Business Insider

Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment

– Study missed primary endpoint of mean time to conversion of SVT to SR over a five-hour period following dosing (p=0.12) – – Etripamil showed rapid conversion of SVT to SR during the first 45 minutes ...
Taiwan News

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...
Medscape

More Good News for Self-Administered Nasal Spray in PSVT

The investigational intranasal L-type calcium channel blocker etripamil continues to be well tolerated and effective for self-treating recurrent episodes of paroxysmal supraventricular tachycardia ...
Monthly Prescribing Reference

Trial Evaluating At-Home PSVT Treatment With Etripamil Nasal Spray Misses Primary End Point

heart ecg Topline results were announced from the phase 3 NODE-301 trial of etripamil nasal spray (Milestone Pharmaceuticals), a novel short-acting calcium channel blocker, being investigated for the ...
Business Insider

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

If approved, etripamil nasal spray is expected to offer patients a safe and effective self-administered treatment option for PSVT outside of the healthcare setting MONTREAL and CHARLOTTE, N.C., Jan.
Monthly Prescribing Reference

Cardamyst Approved for Self-Treatment of PSVT Episodes

Credit: Milestone Pharmaceuticals Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil. Cardamyst is expected to be ...
Labroots

Self-Treating Tachycardia: One Step Closer to an In-Pocket Option

A sudden, rapid heart rate will send many to the emergency room. Every year, more than 140,000 emergency room visits are related to a specific type of increased heart rate called paroxysmal ...
Healio

Self-administered nasal spray ‘rapidly’ treats paroxysmal supraventricular tachycardia

Please provide your email address to receive an email when new articles are posted on . CHICAGO — A fast-acting nasal spray safely and effectively converted episodes of paroxysmal supraventricular ...
Medscape

NODE-1: Simple Nasal Spray May Short-circuit Acute PSVT

CHICAGO, IL — A nasal spray containing the calcium-channel blocker etripamil could allow patients to convert acute paroxysmal supraventricular tachycardia (PSVT) outside the hospital, phase 2 data ...
Mena FN

Milestone Receives FDA Approval Of CARDAMYSTTM (Etripamil) As First And Only Self-Administered Nasal Spray For Adults With Paroxysmal Supraventricular Tachycardia (PSVT)

PSVT, also called SVT, is characterized by episodes of abnormally fast heart rate. Most people with PSVT experience multiple sustained episodes that require treatment on an annual basis. Until now, ...
manilatimes

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

CARDAMYST nasal spray is a novel and rapid-acting calcium channel blocker delivered when needed to treat often highly symptomatic and unpredictable episodes of PSVT. With CARDAMYST, adults with PSVT ...